Fig. 4From: Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysisPooled 1-year (a) and 2-year OS rates (b) for overall patients; pooled OS rates for the ECRT group, 1-year (c), 2-year (d), and 3-year (e) OS rate. OS: overall survival; ECRT: endostatin combined with concurrent chemoradiotherapyBack to article page